Go Pro
→ NASA's ISS Replacement Could Go to This Tiny Space Firm (From Behind the Markets) (Ad)tc pixel Free DMAA Stock Alerts

Drugs Made In America Acquisition (DMAA) Competitors

Drugs Made In America Acquisition logo
$10.82 -0.03 (-0.28%)
As of 09/23/2026 04:00 PM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare

DMAA vs. TUYA, DJCO, RSKD, MGIC, and DSP

Should you buy Drugs Made In America Acquisition stock or one of its competitors? Drugs Made In America Acquisition's main competitors and comparable companies include Tuya (TUYA), Daily Journal Corp. (S.C.) (DJCO), Riskified (RSKD), Magic Software Enterprises (MGIC), and Viant Technology (DSP). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "application software" industry.

How does Drugs Made In America Acquisition compare to Tuya?

Tuya (NYSE:TUYA) and Drugs Made In America Acquisition (NASDAQ:DMAA) are both small-cap technology companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, risk, profitability, valuation and media sentiment.

In the previous week, Tuya had 4 more articles in the media than Drugs Made In America Acquisition. MarketBeat recorded 4 mentions for Tuya and 0 mentions for Drugs Made In America Acquisition. Drugs Made In America Acquisition's average media sentiment score of 0.00 beat Tuya's score of -0.27 indicating that Drugs Made In America Acquisition is being referred to more favorably in the news media.

Company Overall Sentiment
Tuya Neutral
Drugs Made In America Acquisition Neutral

Tuya presently has a consensus price target of $3.69, suggesting a potential upside of 112.68%. Given Tuya's stronger consensus rating and higher probable upside, research analysts clearly believe Tuya is more favorable than Drugs Made In America Acquisition.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Tuya
0 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.50
Drugs Made In America Acquisition
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

11.5% of Tuya shares are owned by institutional investors. 2.1% of Tuya shares are owned by company insiders. Comparatively, 0.9% of Drugs Made In America Acquisition shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Tuya has a beta of 0.56, indicating that its stock price is 44% less volatile than the broader market. Comparatively, Drugs Made In America Acquisition has a beta of 0.01, indicating that its stock price is 99% less volatile than the broader market.

Tuya has a net margin of 20.16% compared to Drugs Made In America Acquisition's net margin of 0.00%. Tuya's return on equity of 6.74% beat Drugs Made In America Acquisition's return on equity.

Company Net Margins Return on Equity Return on Assets
Tuya20.16% 6.74% 5.96%
Drugs Made In America Acquisition N/A N/A N/A

Tuya has higher revenue and earnings than Drugs Made In America Acquisition.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tuya$340.79M2.77$57.89M$0.1115.77
Drugs Made In America AcquisitionN/AN/AN/AN/AN/A

Summary

Tuya beats Drugs Made In America Acquisition on 11 of the 12 factors compared between the two stocks.

How does Drugs Made In America Acquisition compare to Daily Journal Corp. (S.C.)?

Drugs Made In America Acquisition (NASDAQ:DMAA) and Daily Journal Corp. (S.C.) (NASDAQ:DJCO) are both small-cap technology companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, risk, dividends, institutional ownership, earnings, valuation and analyst recommendations.

51.2% of Daily Journal Corp. (S.C.) shares are held by institutional investors. 0.9% of Drugs Made In America Acquisition shares are held by insiders. Comparatively, 0.1% of Daily Journal Corp. (S.C.) shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Drugs Made In America Acquisition has a net margin of 0.00% compared to Daily Journal Corp. (S.C.)'s net margin of -11.63%. Drugs Made In America Acquisition's return on equity of 0.00% beat Daily Journal Corp. (S.C.)'s return on equity.

Company Net Margins Return on Equity Return on Assets
Drugs Made In America AcquisitionN/A N/A N/A
Daily Journal Corp. (S.C.) -11.63%-3.11%-2.24%

Daily Journal Corp. (S.C.) has higher revenue and earnings than Drugs Made In America Acquisition.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Drugs Made In America AcquisitionN/AN/AN/AN/AN/A
Daily Journal Corp. (S.C.)$87.70M10.38$112.14M-$8.22N/A

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Drugs Made In America Acquisition
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Daily Journal Corp. (S.C.)
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00

Drugs Made In America Acquisition has a beta of 0.01, suggesting that its share price is 99% less volatile than the broader market. Comparatively, Daily Journal Corp. (S.C.) has a beta of 0.85, suggesting that its share price is 15% less volatile than the broader market.

In the previous week, Daily Journal Corp. (S.C.) had 2 more articles in the media than Drugs Made In America Acquisition. MarketBeat recorded 2 mentions for Daily Journal Corp. (S.C.) and 0 mentions for Drugs Made In America Acquisition. Daily Journal Corp. (S.C.)'s average media sentiment score of 1.25 beat Drugs Made In America Acquisition's score of 0.00 indicating that Daily Journal Corp. (S.C.) is being referred to more favorably in the news media.

Company Overall Sentiment
Drugs Made In America Acquisition Neutral
Daily Journal Corp. (S.C.) Positive

Summary

Daily Journal Corp. (S.C.) beats Drugs Made In America Acquisition on 6 of the 10 factors compared between the two stocks.

How does Drugs Made In America Acquisition compare to Riskified?

Riskified (NYSE:RSKD) and Drugs Made In America Acquisition (NASDAQ:DMAA) are both small-cap technology companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, risk, dividends, profitability, media sentiment and analyst recommendations.

Riskified presently has a consensus price target of $6.50, suggesting a potential downside of 9.15%. Given Riskified's stronger consensus rating and higher possible upside, analysts plainly believe Riskified is more favorable than Drugs Made In America Acquisition.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Riskified
2 Sell rating(s)
3 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.00
Drugs Made In America Acquisition
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Drugs Made In America Acquisition has lower revenue, but higher earnings than Riskified.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Riskified$368.15M2.88-$27.57M-$0.11N/A
Drugs Made In America AcquisitionN/AN/AN/AN/AN/A

Drugs Made In America Acquisition has a net margin of 0.00% compared to Riskified's net margin of -4.23%. Drugs Made In America Acquisition's return on equity of 0.00% beat Riskified's return on equity.

Company Net Margins Return on Equity Return on Assets
Riskified-4.23% -3.93% -2.79%
Drugs Made In America Acquisition N/A N/A N/A

Riskified has a beta of 1.38, indicating that its share price is 38% more volatile than the broader market. Comparatively, Drugs Made In America Acquisition has a beta of 0.01, indicating that its share price is 99% less volatile than the broader market.

59.0% of Riskified shares are owned by institutional investors. 17.4% of Riskified shares are owned by company insiders. Comparatively, 0.9% of Drugs Made In America Acquisition shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Riskified had 5 more articles in the media than Drugs Made In America Acquisition. MarketBeat recorded 5 mentions for Riskified and 0 mentions for Drugs Made In America Acquisition. Riskified's average media sentiment score of 0.77 beat Drugs Made In America Acquisition's score of 0.00 indicating that Riskified is being referred to more favorably in the media.

Company Overall Sentiment
Riskified Positive
Drugs Made In America Acquisition Neutral

Summary

Riskified beats Drugs Made In America Acquisition on 9 of the 12 factors compared between the two stocks.

How does Drugs Made In America Acquisition compare to Magic Software Enterprises?

Drugs Made In America Acquisition (NASDAQ:DMAA) and Magic Software Enterprises (NASDAQ:MGIC) are both small-cap technology companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, risk, dividends, earnings, media sentiment and valuation.

Magic Software Enterprises has a net margin of 6.61% compared to Drugs Made In America Acquisition's net margin of 0.00%. Magic Software Enterprises' return on equity of 16.28% beat Drugs Made In America Acquisition's return on equity.

Company Net Margins Return on Equity Return on Assets
Drugs Made In America AcquisitionN/A N/A N/A
Magic Software Enterprises 6.61%16.28%8.96%

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Drugs Made In America Acquisition
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Magic Software Enterprises
0 Sell rating(s)
2 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00

In the previous week, Drugs Made In America Acquisition's average media sentiment score of 0.00 equaled Magic Software Enterprises'average media sentiment score.

Company Overall Sentiment
Drugs Made In America Acquisition Neutral
Magic Software Enterprises Neutral

Magic Software Enterprises has higher revenue and earnings than Drugs Made In America Acquisition.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Drugs Made In America AcquisitionN/AN/AN/AN/AN/A
Magic Software Enterprises$603.22M1.41$36.88M$0.8121.46

Drugs Made In America Acquisition has a beta of 0.01, indicating that its share price is 99% less volatile than the broader market. Comparatively, Magic Software Enterprises has a beta of 0.73, indicating that its share price is 27% less volatile than the broader market.

24.7% of Magic Software Enterprises shares are held by institutional investors. 0.9% of Drugs Made In America Acquisition shares are held by company insiders. Comparatively, 4.5% of Magic Software Enterprises shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Magic Software Enterprises beats Drugs Made In America Acquisition on 8 of the 8 factors compared between the two stocks.

How does Drugs Made In America Acquisition compare to Viant Technology?

Viant Technology (NASDAQ:DSP) and Drugs Made In America Acquisition (NASDAQ:DMAA) are both small-cap technology companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, valuation, profitability, earnings, media sentiment, institutional ownership and risk.

Viant Technology has a net margin of 2.24% compared to Drugs Made In America Acquisition's net margin of 0.00%. Viant Technology's return on equity of 4.23% beat Drugs Made In America Acquisition's return on equity.

Company Net Margins Return on Equity Return on Assets
Viant Technology2.24% 4.23% 2.71%
Drugs Made In America Acquisition N/A N/A N/A

In the previous week, Viant Technology had 16 more articles in the media than Drugs Made In America Acquisition. MarketBeat recorded 16 mentions for Viant Technology and 0 mentions for Drugs Made In America Acquisition. Viant Technology's average media sentiment score of 0.40 beat Drugs Made In America Acquisition's score of 0.00 indicating that Viant Technology is being referred to more favorably in the media.

Company Overall Sentiment
Viant Technology Neutral
Drugs Made In America Acquisition Neutral

Viant Technology has a beta of 1.13, suggesting that its share price is 13% more volatile than the broader market. Comparatively, Drugs Made In America Acquisition has a beta of 0.01, suggesting that its share price is 99% less volatile than the broader market.

Viant Technology has higher revenue and earnings than Drugs Made In America Acquisition.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Viant Technology$388.50M2.10$8.35M$0.3139.65
Drugs Made In America AcquisitionN/AN/AN/AN/AN/A

11.4% of Viant Technology shares are owned by institutional investors. 29.4% of Viant Technology shares are owned by company insiders. Comparatively, 0.9% of Drugs Made In America Acquisition shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Viant Technology presently has a consensus price target of $18.33, indicating a potential upside of 49.17%. Given Viant Technology's stronger consensus rating and higher possible upside, equities analysts plainly believe Viant Technology is more favorable than Drugs Made In America Acquisition.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Viant Technology
0 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
3.00
Drugs Made In America Acquisition
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Summary

Viant Technology beats Drugs Made In America Acquisition on 13 of the 13 factors compared between the two stocks.

Get Drugs Made In America Acquisition News Delivered to You Automatically

Sign up to receive the latest news and ratings for DMAA and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DMAA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

DMAA vs. The Competition

Export
MetricDrugs Made In America AcquisitionSoftware IndustryTechnology SectorNASDAQ Exchange
Market Cap$263.40M$15.95B$31.38B$13.29B
Dividend YieldN/A3.41%2.75%12.57%
P/E RatioN/A142.7578.9625.69
Price / SalesN/A1,291.44590.7378.99
Price / CashN/A47.5449.7052.76
Price / BookN/A8.898.016.32
Net IncomeN/A$433.53M$702.96M$359.73M
7 Day Performance0.09%0.49%1.41%0.17%
1 Month Performance0.98%-2.25%-1.06%-3.27%
1 Year Performance5.24%-0.66%178.56%5.58%

Drugs Made In America Acquisition Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
DMAA
Drugs Made In America Acquisition
N/A$10.85
flat		N/A+5.8%$263.40MN/AN/A2
TUYA
Tuya
4.0923 of 5 stars		$1.81
-0.8%		$3.69
+104.4%		-29.6%$977.77M$321.79M16.411,441
DJCO
Daily Journal Corp. (S.C.)
0.7301 of 5 stars		$661.90
+2.2%		N/A+45.4%$912.10M$97.65MN/A320
RSKD
Riskified
2.1789 of 5 stars		$6.07
+1.6%		$6.50
+7.2%		+51.4%$902.25M$344.64MN/A780
MGIC
Magic Software Enterprises
N/A$17.38
flat		N/AN/A$853.36M$603.22M21.463,787

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:DMAA) was last updated on 9/24/2026 by MarketBeat.com Staff.
From Our Partners
How to get a stake in Anthropic — before the IPO
Anthropic, the maker of Claude AI, has reportedly filed for an IPO that could arrive as early as October. Its ...
Weiss Ratings | Sponsoredtc pixel
If you keep cash in a U.S. bank account… read this NOW
Since 2020, U.S. banks have been required to keep zero percent of deposits on hand, lending out nearly every d...
Banyan Hill Publishing | Sponsoredtc pixel
Why I believe the AI market will split in Q4
Matt McCall, who recommended Nvidia near $6 a share, says the AI market is splitting in two - just like the do...
The Oxford Club | Sponsoredtc pixel
Shocking new footage just released
Gerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...
Digest Publishing | Sponsoredtc pixel
On October 7th, your “safest” assets are at risk
Jeff Brown called Nvidia's rise of over 27,000 percent and warned in early 2024 that inflation would outlast W...
Brownstone Research | Sponsoredtc pixel
While SpaceX Gets the Spotlight, FJET Is Building What Comes Next!
Starfighters Space (NYSE: FJET) operates the world's only commercial fleet of flight-ready Mach 2+ F-104 Starf...
Trading Wire | Sponsoredtc pixel
The REAL Reason 2,000 Missiles Rained on Iran
Two private meetings with U.S. Congressmen and weeks of research point to a surprising explanation for the rec...
Behind the Markets | Sponsoredtc pixel
This free guide explains options the way they should be taught
Most options educators jump straight into Greeks, spreads, and implied volatility - losing beginners before th...
Base Camp Trading | Sponsoredtc pixel